Leadership

Adam Simpson

Adam Simpson

Chief Executive Officer

Adam Simpson is the chief executive officer (CEO) of Icosavax. He has substantial life science operational and emerging company experience and has executed significant partnering and acquisition transactions. Previously, Adam was CEO of PvP Biologics, another spinout from University of Washington’s Institute for Protein Design (IPD), from company creation through its sale to Takeda. Prior to joining PvP Biologics, he was the president and chief operating officer of Cypher Genomics, a genome interpretation company focused on biomarker discovery to facilitate

Douglas Holtzman, Ph.D., MPH

Douglas Holtzman, Ph.D., MPH

Chief Scientific Officer

Douglas Holtzman, Ph.D., MPH is the chief scientific officer (CSO) of Icosavax. He has 25 years of experience in industry and the philanthropic sector leading and funding innovative research and development activities with an emphasis on vaccines. Prior to Icosavax, he was vice president, Discovery at Takeda Pharmaceuticals, where he led a team working on dengue and norovirus vaccine candidates. He was also a member of the management committee that helped to globalize Takeda’s Japan-based vaccines business. Prior to Takeda,

Niranjan Kanesa-thasan, M.D., MTMH, FIDSA, FASTMH

Niranjan Kanesa-thasan, M.D., MTMH, FIDSA, FASTMH

Chief Medical Officer

Niranjan Kanesa-thasan, M.D., MTMH, FIDSA, FASTMH is the chief medical officer of Icosavax and is a global medical executive with a successful 25-year career in vaccine research and development leading to seven licensed vaccines. He has extensive leadership and management experience in the biopharmaceutical industry (vice president, GSK Vaccines and Novartis Vaccines; Acambis, acquired by Sanofi Pasteur), government (Walter Reed Army Institute for Research, US Army Medical Research Institute for Infectious Diseases), and academia (Uniformed Services University of the Health

Cassia Cearley, Ph.D.

Cassia Cearley, Ph.D.

Chief Business Officer

Cassia has worked with pharmaceutical companies in various roles for over 10 years. Prior to joining Icosavax, Cassia was the vice president of research for Aptinyx Inc., where she led a team responsible for building a portfolio of small molecule NMDA receptor modulators. Prior to this, Cassia was on the corporate development team of Naurex Inc, which was responsible for the spinout of Aptinyx Inc. and the sale of Naurex to Allergan. Previously, Cassia worked at Takeda Pharmaceuticals, where she

Charles Richardson, Ph.D.

Charles Richardson, Ph.D.

Senior Vice President, Technical Operations

Charles (Chuck) Richardson, Ph.D. is the senior vice president (SVP), Technical Operations of Icosavax, with responsibility for CMC development and manufacturing for Icosavax vaccines. Chuck has more than thirty years of experience in biopharmaceutical development with demonstrated leadership capability in a global environment. His experience includes planning, implementing, and managing research and product development, as well as manufacturing and engineering and quality systems. Prior to joining Icosavax, he was vice president, head of Global CMC for Takeda Vaccines, with responsibility

Board of Directors

Tadataka (Tachi) Yamada, M.D.

Chair

Jason Hafler

Director

Eric Moessinger

Director

Terry Gould

Director

Mark McDade

Director

Adam Simpson

Chief Executive Officer

Scientific Advisory Board
and Key Advisors

Neil King, Ph.D.

Chair, Scientific Advisory Board

Ralf Clemens, M.D.

Development Advisor and SAB Member

Jean-Paul Prieels, Ph.D.

SAB Member

David Baker Ph.D.

Co-founder

Christian Mandl, M.D., Ph.D.

SAB Member

Barney S. Graham, M.D., Ph.D.

SAB Member